Abstracts tagged "Disease Activity"

Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 1357 • ACR Convergence 2025
Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
Jue Hou¹, Feiqing Huang², Gregory McDermott³, Jun Wen⁴, Mary Jeffway³, Ying Qi⁵, Yunqing Han³, Tianrun Cai⁶, Florence Bourgeois⁴, Katherine Liao⁷ and Tianxi Cai², ¹University of Minnesota, Minneapolis, MN, ²Harvard T.H. Chan School of Public Health, Boston, ³Brigham and Women's Hospital, Boston, ⁴Harvard Medical School, Boston, ⁵Brigham and Women’s Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: Validated rheumatoid arthritis (RA) disease activity measures such as the Disease Activity Score-28 (DAS28) are used in clinical trials but not universally recorded in…
Abstract Number: 1499 • ACR Convergence 2025
Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis
Michelle Petri¹, Andrea Fava², Daniel Goldman¹ and Laurence Magder³, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Over 20% of lupus nephritis (LN) patients progress to end stage kidney disease. One of the most important predictors is renal flare.Methods: The analysis…
Abstract Number: 1973 • ACR Convergence 2025
Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic
Madana Kamineni¹, Janelle Vircks¹, Jessica Lynton¹, Clarisse Purvis¹ and Brittany Panico², ¹Optum, Gilbert, AZ, ²Summit Rheumatology, Gilbert, AZ
Background/Purpose: Existing data demonstrate that clinical pharmacist integration in rheumatology clinics improves provider satisfaction, patient outcomes, medication adherence, and RAPID-3 (Routine Assessment of Patient Index…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 2564 • ACR Convergence 2025
An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
Mie Fusama¹, Hideko Nakahara², Megumi Okada³, Kayoko Sakagami⁴, Ikuyo Noguchi⁵, Harumi Matsumura⁶, Hiroaki Ito⁴, Kosaku Oda⁵, Yoshitaka Shinto³, Kenshi Higami⁶, Satomi Higami⁶ and Tetsuya Tomita⁷, ¹Kansai University of International Studies, Miki, Japan, ²Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, ³Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, ⁴Infusion Clinic, Osaka, Japan, ⁵Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, ⁶Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, ⁷Morinomiya University of Medical Sciences, Osaka, Japan
Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
Abstract Number: 0260 • ACR Convergence 2025
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Lachelle D. Weeks¹, Danielle Hammond², Sinisa Savic³, Mael Heiblig⁴, Onima Chowdhury⁵, Arsène Mekinian⁶, Carmelo Gurnari⁷, Radhakrishanan Ramchandren⁸, Sophie georgin-Lavialle⁹, Marcela ferrada¹⁰, Sarah A. Buckley¹¹, Bryan G. harder¹¹, Sandra Goble¹¹, David Beck¹² and Matthew Koster¹³, ¹Dana Farber Cancer Institute, Boston, MA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁶Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁷Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁸University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁰University of Maryland, Bethesda, MD, ¹¹Sobi Inc., Waltham, MA, ¹²Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
Abstract Number: 0451 • ACR Convergence 2025
Menopause Status and Disease Activity in Rheumatoid Arthritis
Katherine Bracamontes¹, David Kellner², Lucia Chen³, David Elashoff⁴, Jenny Brook⁵ and Veena Ranganath², ¹Division of Internal Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA, ³UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA, ⁴UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, ⁵UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA
Background/Purpose: In women, rheumatoid arthritis (RA) commonly presents around menopause, a timing thought to be influenced by the decline of estrogen and progesterone. However, the…
Abstract Number: 0805 • ACR Convergence 2025
Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
Jacquelyn Nestor¹, Zahraa Qamhieh², Shivani Garg³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Wisconsin, Madison, Department of Medicine, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a foundational therapy in systemic lupus erythematosus (SLE) treatment, as it prolongs disease-free and damage-free survival. However, the optimal dose is…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 1364 • ACR Convergence 2025
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Prativa Priyadarshani Sethi¹, Venkatesh Srinivasa Pai², Rajat Ranka², Avneet Kumar Gupta³, Ashish Baweja⁴, ritu sangwan⁵, Abhishek Rai⁶, Sryla Punjadath¹ and Nithya Maskani², ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, ³AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, ⁴Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, ⁵AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ⁶AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…
Abstract Number: 2058 • ACR Convergence 2025
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
valeria cantu¹, Emmanuel Dominguez-Chapa², Rebeca L. Polina-Lugo¹, Ana Cecilia Bardan Inchaustegui³, fernanda m. garcia-Carrillo⁴, Ericka S. Reyna-Hernandez⁵, Daniela A. Mejia-Rodriguez⁵, Rosa Arvizu-Rivera⁶, Jesus Alberto Cardenas-de la Garza⁷, Miguel Villarreal-Alarcón⁸ and Dionicio A. Galarza-Delgado⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
Abstract Number: 2295 • ACR Convergence 2025
Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Deepak Rath¹, Sholen Acharya² and Dr Alakendu Ghosh³, ¹John H Stroger Hospital Jr of Cook County, Chicago, Illinois, USA, ⁶⁰⁶¹², Chicago, IL, ²Department of Reproductive Medicine and Surgery, Government Medical College Thiruvananthapuram, Kerala, India, ⁶⁹⁵⁰⁰⁴, Chicago, IL, ³Self employed, Kolkata, West Bengal, India
Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].